Big Pharma For Your Pets — And It's Down Over 50%
1 extracted signal · 0 resolved · 1 still active
Lou BaseneseIndependent analyst profile- Source published
- 15 Aug 2026, 16:30 UTC
- Recorded by Tahlil Plus
- 15 Aug 2026, 16:52 UTC
AI-generated source summary
The speaker identifies Zoetis (ZTS) as a beaten-down stock that is currently cheap, with a potential for significant upside. The analysis suggests that ZTS is a value play in an expensive market, with an anticipated rally of 40-50% before the end of the year. This rally is expected to be driven by a rebound in the company's results and continued consumer spending on pets. The current pre-market price is $74.13, and the predicted target is approximately $103.78, representing a 40% increase. The failure bound for this bullish thesis is set at $60.0, below which the analysis would be invalidated.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Lou Basenese
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.